Kedar Kirtane

1.4k total citations
61 papers, 743 citations indexed

About

Kedar Kirtane is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kedar Kirtane has authored 61 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 17 papers in Otorhinolaryngology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kedar Kirtane's work include Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (17 papers) and Head and Neck Cancer Studies (17 papers). Kedar Kirtane is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (17 papers) and Head and Neck Cancer Studies (17 papers). Kedar Kirtane collaborates with scholars based in United States, Taiwan and Palestinian Territory. Kedar Kirtane's co-authors include Christine H. Chung, Stephanie J. Lee, Daniel Abate‐Daga, Hany Elmariah, Jameel Muzaffar, Shahla Bari, Laura B. Oswald, Sarah Buckley, Gary H. Lyman and Roland B. Walter and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Kedar Kirtane

53 papers receiving 739 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kedar Kirtane United States	12	410	176	133	118	105	61	743
Simona Secondino Italy	18	687 1.7×	261 1.5×	206 1.5×	227 1.9×	55 0.5×	59	1.2k
Deborah Marcellus United States	19	555 1.4×	251 1.4×	126 0.9×	98 0.8×	104 1.0×	30	1.2k
Willem M. Smit Netherlands	14	422 1.0×	356 2.0×	104 0.8×	71 0.6×	72 0.7×	36	934
Nagashree Seetharamu United States	14	494 1.2×	149 0.8×	251 1.9×	261 2.2×	40 0.4×	99	984
Sam Penza United States	17	321 0.8×	188 1.1×	103 0.8×	59 0.5×	134 1.3×	63	806
Raja Pramanik India	14	222 0.5×	25 0.1×	165 1.2×	126 1.1×	47 0.4×	95	574
Mark T. Wakabayashi United States	20	444 1.1×	244 1.4×	152 1.1×	116 1.0×	57 0.5×	55	1.1k
Gavin Cull Australia	17	367 0.9×	217 1.2×	112 0.8×	70 0.6×	128 1.2×	67	1.2k
Mohammad Vaezi Iran	13	133 0.3×	81 0.5×	122 0.9×	59 0.5×	49 0.5×	93	511
Hyun‐Jeong Shim South Korea	19	329 0.8×	50 0.3×	202 1.5×	227 1.9×	105 1.0×	50	824

Countries citing papers authored by Kedar Kirtane

Since Specialization

Citations

This map shows the geographic impact of Kedar Kirtane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kedar Kirtane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kedar Kirtane more than expected).

Fields of papers citing papers by Kedar Kirtane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kedar Kirtane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kedar Kirtane. The network helps show where Kedar Kirtane may publish in the future.

Co-authorship network of co-authors of Kedar Kirtane

This figure shows the co-authorship network connecting the top 25 collaborators of Kedar Kirtane. A scholar is included among the top collaborators of Kedar Kirtane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kedar Kirtane. Kedar Kirtane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reblin, Maija, et al.. (2025). The patient and caregiver experience of CAR T-cell therapy: A qualitative analysis. Journal of Psychosocial Oncology. 43(6). 875–885. 1 indexed citations

Gibbs, Heather, Jessica Hamilton, Nathan H. Parker, et al.. (2025). Nutrition in head and neck cancer care: a roadmap and call for research. The Lancet Oncology. 26(6). e300–e310. 1 indexed citations

Shen, Colette J., Jessica M. Frakes, Trevor Hackman, et al.. (2024). Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.. Journal of Clinical Oncology. 42(16_suppl). 6035–6035. 3 indexed citations

Simeone, Diane M., Patrick Grierson, Kedar Kirtane, et al.. (2024). Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).. Journal of Clinical Oncology. 42(16_suppl). 1604–1604.

Punekar, Salman R., J. Randolph Hecht, Diane M. Simeone, et al.. (2024). EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).. Journal of Clinical Oncology. 42(16_suppl). TPS2699–TPS2699. 5 indexed citations

Pearson, Alexander T., Kedar Kirtane, Emily L. Bellile, et al.. (2024). Phase I/II Study of A Novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers. International Journal of Radiation Oncology*Biology*Physics. 118(5). e6–e7. 2 indexed citations

Tasoulas, Jason, Travis P. Schrank, Jay Mehta, et al.. (2024). Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites. Scientific Reports. 14(1). 15821–15821. 4 indexed citations

Yang, Qidi, Mario G. Rosasco, John S. Welch, et al.. (2024). Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities. npj Precision Oncology. 8(1). 174–174. 5 indexed citations

Johnston, Fabian M., Ana P. Kiess, Kedar Kirtane, et al.. (2024). The History and Future of Multidisciplinary Cancer Care. Seminars in Radiation Oncology. 34(4). 441–451. 1 indexed citations

10.

Kirtane, Kedar, et al.. (2023). Demographic disparities in receipt of care at a comprehensive cancer center. Cancer Medicine. 12(12). 13687–13700. 6 indexed citations

11.

Echevarria, Michelle, G.Q. Yang, Dung‐Tsa Chen, et al.. (2023). Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 117(2). 341–347. 7 indexed citations

12.

Oswald, Laura B., Naomi C. Brownstein, Junmin Whiting, et al.. (2022). Smoking Is Related to Worse Cancer-related Symptom Burden. The Oncologist. 27(2). e176–e184. 8 indexed citations

13.

Yilmaz, Emrullah, Nofisat Ismaila, Julie E. Bauman, et al.. (2022). Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. Journal of Clinical Oncology. 41(5). 1132–1146. 49 indexed citations

14.

Kirtane, Kedar, et al.. (2022). Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time. Leukemia & lymphoma. 64(2). 364–370. 3 indexed citations

15.

Wang, Xuefeng, Jameel Muzaffar, Kedar Kirtane, et al.. (2022). T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(6). e004512–e004512. 21 indexed citations

16.

Kirtane, Kedar, Aasha I. Hoogland, Christine H. Chung, et al.. (2022). “I have cancer during COVID; that’s a special category”: a qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic. Supportive Care in Cancer. 30(5). 4337–4344. 11 indexed citations

17.

Oswald, Laura B., Yi Luo, Xiaoyin Li, et al.. (2022). Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis. Blood. 140(Supplement 1). 10913–10915. 1 indexed citations

18.

Oswald, Laura B., Xiaoyin Li, Rodrigo Carvajal, et al.. (2022). Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. Cancers. 14(11). 2742–2742. 14 indexed citations

19.

Tan, Elaine, et al.. (2021). TCR gene-engineered cell therapy for solid tumors. Best Practice & Research Clinical Haematology. 34(3). 101285–101285. 16 indexed citations

20.

Kirtane, Kedar, Lois Downey, Stephanie J. Lee, J. Randall Curtis, & Ruth A. Engelberg. (2018). Intensity of End-of-Life Care for Patients with Hematologic Malignancies and the Role of Race/Ethnicity. Journal of Palliative Medicine. 21(10). 1466–1471. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact